Rapid Micro Biosystems Q3 Revenue Rises
Rapid Micro Biosystems reported Q3 2026 revenue of $9.5 million, up 22%, alongside a record 25.2% gross margin. Meanwhile, the company announced it has entered into a definitive agreement to be acquired by Merck KGaA.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed